Why is "Pitolisant" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-17 15:14:58
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Pitolisant entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-17 and was most recently seen on 2026-07-17.
Wikipedia Overview
Pitolisant, sold under the brand name Wakix among others, is a medication used for the treatment of excessive daytime sleepiness in adults with narcolepsy. It is an inverse agonist of the histamine H3 receptor. It is the first commercially available medication in its class; the U.S. Food and Drug Administration (FDA) designated it a first-in-class medication. Pitolisant enhances the activity of histaminergic neurons in the brain that function to improve a person's wakefulness.
It was approved by the European Medicines Agency (EMA) in March 2016 for narcolepsy with or without cataplexy, and for excessive daytime sleepiness by the FDA in August 2019. The most common side effects include difficulty sleeping, nausea, and feeling worried.
Related Topics
- Narcolepsy
- Cataplexy
- Lisdexamfetamine
- Clomipramine
- 2-Pyridylethylamine
- 4-Methyldiphenhydramine
- 4-Methylhistamine
- 5-HT2A receptor
- A-349821
- A-423579
Trending Topic Today
Search Interest Perspective
-
FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy - NeurologyLive
-
FDA approves Wakix for cataplexy in pediatric narcolepsy - American Academy of Sleep Medicine | AASM
-
Pitolisant Showed Sustained Benefit in Adults With Idiopathic Hypersomnia in New Phase 3 Trial - Patient Care Online
-
FDA Approves Pitolisant for Treatment of Cataplexy in Pediatric Narcolepsy - pharmacytimes.com
-
Evaluating Pitolisant and Other Pharmacologic Treatment Options for Narcolepsy - Psychiatric Times
-
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX - Business Wire
-
Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets - PR Newswire
-
Harmony Advances Pitolisant GR After Bioequivalence Success - Sleep Review
-
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up - tradingview.com
-
FDA Expands Use of Pitolisant for Pediatric Patients With Narcolepsy With Cataplexy - Drug Topics
-
Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance - Yahoo Finance
-
Pitolisant Inhibits Alcohol Drinking and Improves Withdrawal Negative Affect Through Lateral Habenula Histaminergic Signaling in Mice - Wiley Online Library
-
Pitolisant shown to reduce daytime sleepiness in PWS, especially in kids - Prader-Willi Syndrome News
-
Wakix: FDA Expands Approval to Treat Sudden Muscle Weakness in Children With Narcolepsy - WebMD
-
Balt's Squid Receives Premarket Approval, Pitolisant Tablets Granted Extended Approval Indication, I-ACQUIRE Displays Promising Short-Term Outcomes - NeurologyLive
-
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026 - Sleep Review
-
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region - PR Newswire
-
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities - Business Wire
-
Assessing DEA Scheduling and Emerging Therapies in Narcolepsy - Psychiatric Times
-
Harmony Biosciences’ Four Key Pillars to Drive Value Creation - Sleep Review
-
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline - tradingview.com
-
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile - Stock Titan
-
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - Business Wire
-
Histamine boost helps the brain remember, decide, and learn from loss - News-Medical
-
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion - Business Wire
-
Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease - Nature
-
Interim Analysis Reveals Long-Term Efficacy and Safety of Pitolisant in Narcolepsy Types 1 and 2 - NeurologyLive
-
Lupin receives tentative approval from USFDA for Pitolisant tablets - Business Standard
-
FDA Rejects Pitolisant NDA for Idiopathic Hypersomnia - HCPLive
-
Lupin receives USFDA tentative approval for Pitolisant Tablets, 4.45mg and 17.8mg - Business Standard
-
Lupin Secures USFDA Tentative Approval for Pitolisant Tablets, Expands CNS Portfolio - eHealth Magazine
-
Pitolisant Reduces Excessive Daytime Sleepiness and Fatigue in Myotonic Dystrophy Type 1 - NeurologyLive
-
Pitolisant Shows Benefit for IH in Phase 3 Open-Label Trial, with Bruce Corser, MD - HCPLive
-
Lupin Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg - scanx.trade
-
Pitolisant found to reduce fatigue, daytime sleepiness in DM1 patients - Muscular Dystrophy News
-
Lupin FDA Nod for Pitolisant; Shares Edge Up 0.41% - HDFC Sky
-
FDA gives Lupin tentative nod for generic Wakix - Drug Store News
-
Harmony Advances Pitolisant High-Dose Development Program - Sleep Review
-
Despite Missing Primary End Point, Pitolisant Shows Positive Outcomes in Phase 3 INTUNE Trial for Idiopathic Hypersomnia - NeurologyLive
-
Lupin receives tentative approval from US FDA for Pitolisant tablets - Express Pharma
-
Case Study and Overview of WAKIX® (pitolisant) Tablets in the Treatment of Excessive Daytime Sleepiness and/or Cataplexy in Adults with Narcolepsy - NeurologyLive
-
Role of Pitolisant in Management of Narcolepsy - Psychiatric Times
-
Harmony Biosciences Downgrades Put Wakix Patent Risks In Sharp Focus - Yahoo Finance
-
Harmony Biosciences to present six posters at SLEEP 2026 - scanx.trade
-
Pitolisant safe, lowers daytime sleepiness in OSA over 1 year - healio.com
-
HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA - PR Newswire
-
Pitolisant: Mechanism of Action - NeurologyLive
-
Viatris Completes Aculys Pharma Acquisition - citybiz
-
FDA Approves Pitolisant for Excessive Daytime Sleepiness in Pediatric Narcolepsy - NeurologyLive
-
Phase 3 Study of Pitolisant in Prader-Willi Syndrome Updates Following Positive FDA Meeting - NeurologyLive
-
FDA disrupts Harmony's expansion dreams for excessive sleepiness drug Wakix with refusal letter - Fierce Pharma
-
Pitolisant Performs Well on Secondary Outcomes in Phase 2 Study of Prader-Willi Syndrome - NeurologyLive
-
Harmony looks past FDA rejection of Wakix towards high-dose formula's potential - FirstWord Pharma
-
Harmony’s Wakix Surpasses $2B in Revenue, Data Shows Promise for IH Treatment - Sleep Review
-
Lupin gets FDA tentative nod for excessive daytime sleepiness drug - pharma.economictimes.indiatimes.com
-
ABBV-951 Gets Another CRL, Pitolisant Approved for Pediatric Narcolepsy, FDA Clears Efgartigimod for CIDP - NeurologyLive
-
Pitolisant Safe and Effective in Children With Narcolepsy - MedPage Today
-
Approved sNDA: Wakix for Treatment of Excessive Daytime Sleepiness in Youth With Narcolepsy - Psychiatric Times
-
Pitolisant for Narcolepsy and EDS: FDA Approval and Personal Experience - NeurologyLive
-
Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity - NeurologyLive
-
Harmony Biosciences Reports Continued Momentum for Pitolisant - Sleep Review
-
Top news of August: Tezepelumab breakthrough designation, pitolisant use in OSA - healio.com
-
Harmony Biosciences reports positive Phase II DM1 therapy data - Clinical Trials Arena
-
Pitolisant and the Role of Histamine in Narcolepsy - Psychiatric Times
-
FAERS Data Analysis Reveals Insights on Safety Profiles of Narcolepsy Treatments - NeurologyLive
-
Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome - Pharmaceutical Technology
-
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy - PR Newswire
-
Pitolisant Improves Fatigue in Myotonic Dystrophy Patients - Sleep Review
-
Safety of pitolisant: a study in the WHO international pharmacovigilance database - Springer Nature Link
-
Lupin rises on getting tentative approval for Pitolisant Tablets from USFDA - Investment Guru India
-
Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy - BioSpace
-
Comparing Treatments for Excessive Daytime Sleepiness in OSA - Docwire News
-
Pitolisant: a novel therapy for narcolepsy and other rare neurological disorders - UCL | University College London
-
Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy - PR Newswire
-
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder - Yahoo Finance
-
Harmony Biosciences obtains favorable settlement in litigation over generic Wakix - Drug Store News
-
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLISANT) - PR Newswire
-
WAKIX (Pitolisant) Safety and Efficacy Data Published in SLEEP - Sleep Review
-
Harmony Biosciences Acquires US Rights to Pitolisant From Bioprojet; Raises $270 Million in Equity Financing - PR Newswire
-
UCL histamine research leads to revolutionary new drug for treating narcolepsy - UCL | University College London
-
Narcolepsy patients face drug shortages, rising costs as key medications are discontinued in Korea - koreabiomed.com
-
Advances in the Treatment of Narcolepsy With Cataplexy: Role of Selective Histamine Receptor Modulation - Neurology Advisor
-
RareStone Group's narcolepsy drug gets Chinese approval - Labiotech.eu
-
FDA Approves Harmony Biosciences’ Wakix to Treat Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy - Pharmaceutical Executive
-
Wakix: Safety during pregnancy, breastfeeding, and more - Medical News Today
-
Bioprojet: WAKIX® (pitolisant) receives approval for the treatment of narcolepsy in children over 6 years of age, a rare, under-diagnosed condition - PR Newswire UK
-
Q1 Sleep Medicine Updates - HCPLive
-
Paladin Labs Announces Approval of WAKIX® (pitolisant hydrochloride tablets) For Use in Pediatric Patients in Canada - PR Newswire Canada
-
Wakix Indication Expanded to Include Cataplexy Treatment - Medical Professionals Reference
-
Newer Agents for the Management of Narcolepsy - Psychiatric Times
-
Bioprojet: European Marketing Authorisation for OZAWADE™ - PR Newswire
-
EMA nod for excessive daytime sleepiness med Ozawade - PharmaTimes
-
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST - PR Newswire
-
RareStone’s narcolepsy therapy receives approval in China - Pharmaceutical Technology
-
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial - The Lancet
-
Patients with sleep disorders in Korea face limited treatment options due to drug pricing system - koreabiomed.com
-
Excessive Daytime Sleepiness In Obstructive Sleep Apnoea Syndrome: Favourable Opinion From The European Medicines Agency For Ozawade™ - PR Newswire
-
Scorpion Stings Harmony with Citizen’s Petition Threat for Sleepiness Drug - BioSpace
-
Harmony Biosciences scores first approval in narcolepsy med Wakix - Fierce Pharma
-
FDA approves first non-controlled substance narcolepsy drug - Pharmaceutical Technology
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.